Baxter Ventures

Medela is a company dedicated to transforming scientific research into practical healthcare solutions that support the health of mothers and infants. Specializing in breast milk feeding and baby products, Medela focuses on understanding the anatomy of the lactating breast and infant sucking patterns to address early breastfeeding challenges. Their offerings include research-based products designed to facilitate breastfeeding, as well as healthcare solutions aimed at hospitals and clinical education. By prioritizing customer feedback and observational research, Medela fosters a commitment to nurturing health for generations.

NovaXS Biotech is focused on creating a next-generation needle-free drug delivery platform aimed at enhancing medication adherence and optimizing treatment outcomes. The company is developing a needle-free injector that utilizes an artificial intelligence-driven health span diagnostic system, allowing for the delivery of proactive, accessible, and personalized medications specifically for age-related diseases. In addition to its innovative injector, NovaXS is establishing a preventive healthcare center dedicated to treating age-related conditions. By leveraging advanced technology, the company aims to empower doctors in their efforts to prevent chronic diseases and address immune system disorders, ultimately striving to improve health span and quality of life for patients.

Medically Home Group, Inc. is a Boston-based company that specializes in delivering virtual hospital services, enabling patients to receive medical care in the comfort of their homes. Founded in 2016, the company offers a comprehensive program that addresses various medical conditions, including heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), and urinary tract infections, among others. By utilizing a technology-enabled platform, Medically Home connects patients with caregivers and facilitates monitoring and communication for individuals with high-acuity illnesses. This approach allows patients and their families to access centralized, on-demand acute medical care management, effectively shifting the focus of healthcare from traditional hospital settings to home-based care.

Walela is a medical device company based in Chicago, Illinois, founded in 2021 by James Balman. The company specializes in sensor technology aimed at enhancing fetal and maternal health outcomes. Its innovative devices measure fetal heart rate and blood pH, providing critical diagnostics for expectant mothers and healthcare professionals. By facilitating accurate assessments of fetal health, Walela's technology helps to reduce the need for unnecessary cesarean sections, thereby improving the overall birthing experience.

Hill-Rom Holdings is an American company based in Chicago, Illinois, specializing in medical technologies for the healthcare industry. The company manufactures a wide range of products, including hospital equipment and supplies such as patient support systems, hospital beds for various acuity settings, and non-invasive therapeutic devices for acute and chronic conditions. Additionally, Hill-Rom offers safe mobility and handling solutions, surgical products, equipment rentals, and information technology solutions aimed at enhancing patient care and advancing healthcare innovations.

Hospital IQ LLC specializes in developing cloud-based software aimed at enhancing operational efficiency in hospitals. The company offers a predictive analytics platform that optimizes surgical scheduling, inpatient capacity, and discharge processes while reducing wait times and length of stay. By combining artificial intelligence, machine learning, and advanced data analytics, the platform provides hospital administrators and clinical department heads with actionable insights to improve decision-making and resource allocation. Hospital IQ's solutions are designed to streamline operations, improve patient flow, and ultimately enhance clinical outcomes and financial performance. Founded in 2013 and based in Newton, Massachusetts, Hospital IQ collaborates with leading healthcare institutions to address operational challenges and support quality improvement initiatives.

Alvotech is a fully integrated biopharmaceutical company dedicated to the development and manufacture of high-quality biosimilar medicines. Founded in 2013 by Róbert Wessman in Reykjavík, the company aims to enhance patients' health and quality of life worldwide by increasing access to effective therapies for various ailments. Through its focus on biosimilars, Alvotech strives to provide proven treatments that address the needs of patients globally.

Medasense is a company specializing in pain monitoring technology aimed at optimizing and personalizing pain management for patients. Its flagship product, the PMD-200, utilizes a proprietary non-invasive sensor platform and artificial intelligence to objectively monitor and quantify a patient's pain response through the NOL® index. This device is particularly beneficial in operating rooms and critical care settings where patients cannot communicate, addressing a significant market need. Medasense also offers pipeline cloud-based solutions that leverage NOL technology for use in clinics and home care, targeting an even larger global market. The PMD-200 is distributed in Europe by Medtronic and has received clearance for marketing in Canada, Latin America, and Australia, with capabilities for integration with Philips patient monitors. Clinical studies have highlighted its effectiveness in improving patient safety and outcomes while reducing opioid usage. Founded in 2008, Medasense is headquartered in Ramat Gan, Tel Aviv, Israel.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing applications and games aimed at managing chronic health conditions and improving patient adherence. Established in 2008, Ayogo employs behavioral psychology and social gaming principles to enhance health outcomes, serving a diverse clientele that includes insurers, healthcare providers, and pharmaceutical companies. The company's flagship product, GoodLife, is a customizable platform featuring gamification elements, incentives, and social interaction, while its suite of Alternate Reality Games integrates online and real-world experiences to facilitate learning. Ayogo's platform is designed to tailor content and support to individual psychosocial factors, promoting patient engagement by fostering activation and adherence to therapy. With a collaborative approach involving patients and clients, Ayogo emphasizes thoughtful innovation within its creative studio environment.

toSense, Inc. is a healthcare technology company based in San Diego, California, focused on developing innovative solutions for at-home monitoring of chronic illnesses, particularly for patients with conditions such as congestive heart failure and chronic obstructive pulmonary disease. The company's flagship product, the CoVa Monitoring System, is a wearable sensor designed to monitor various health parameters, including thoracic impedance, heart rate, and respiration rate. This device, worn as a necklace and secured with disposable electrodes, transmits vital signs to gateways that relay the data to a web-based system for clinical review. This technology allows healthcare providers to detect potential issues earlier than traditional monitoring methods, enabling timely intervention. Established in 2008 and formerly known as Perminova, Inc., toSense operates as a subsidiary of Baxter International Inc. and aims to address pressing medical challenges through its hardware and software solutions.

Seprafilm is a mechanical bioresorbable adhesion barrier designed to be applied to adhesiogenic tissues prior to surgical closure. Its primary purpose is to reduce the incidence, extent, and severity of postoperative adhesions in patients undergoing abdominal or pelvic laparotomy. By serving as an adjunct in surgical procedures, Seprafilm aims to mitigate the risks associated with adhesions that can occur between the abdominal wall and underlying viscera, thereby enhancing surgical outcomes and patient recovery.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Prescient Surgical, Inc. develops medical devices aimed at preventing surgical site infections, specifically for patients undergoing high-risk abdominal gastrointestinal surgeries. The company's flagship product, CleanCision, features a wound retraction and protection system that integrates wound protection with continuous irrigation. This system effectively clears harmful bacteria that may invade surgical incisions, thereby enhancing patient outcomes and reducing healthcare costs. Incorporated in 2012, Prescient Surgical is based in San Carlos, California.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Bugworks Research Inc. is a biotechnology company focused on developing innovative antibiotics to combat antimicrobial resistance (AMR). Founded in 2014, the company operates from its headquarters in Saratoga, California, with additional offices in Adelaide, Australia, and Bengaluru, India. Bugworks specializes in creating a new class of antibiotic drugs designed to withstand drug resistance, offering products such as GYROX-1, an intravenous solution for critical care infections; GYROX-2, an oral treatment for various infections; and GYROX-3, specifically for cystic fibrosis patients. The company's research platform emphasizes broad-spectrum assets and leverages expertise in cancer biology and immunology to address the challenges posed by drug resistance in healthcare.

Claris Injectables Limited is a global pharmaceutical company specializing in sterile injectable drugs. As a wholly-owned subsidiary of Claris Lifesciences Limited, it manufactures and markets a diverse range of products across various therapeutic areas, including anesthesia, anti-infectives, critical care, and nephrology. The company primarily focuses on generic injectable medications used to treat critical illnesses, serving a customer base that includes government institutions, corporate hospitals, and nursing homes. Claris Injectables operates three manufacturing facilities located in Ahmedabad, India, which have received approvals from multiple regulatory bodies, including the US FDA and MHRA in the UK. The company emphasizes quality and innovation, offering a variety of technology-driven injectable products in different delivery systems, such as vials, ampoules, and bags. Claris Injectables has garnered recognition for its manufacturing excellence and has a skilled workforce across various functions, including product development and regulatory affairs.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Medasense is a company specializing in pain monitoring technology aimed at optimizing and personalizing pain management for patients. Its flagship product, the PMD-200, utilizes a proprietary non-invasive sensor platform and artificial intelligence to objectively monitor and quantify a patient's pain response through the NOL® index. This device is particularly beneficial in operating rooms and critical care settings where patients cannot communicate, addressing a significant market need. Medasense also offers pipeline cloud-based solutions that leverage NOL technology for use in clinics and home care, targeting an even larger global market. The PMD-200 is distributed in Europe by Medtronic and has received clearance for marketing in Canada, Latin America, and Australia, with capabilities for integration with Philips patient monitors. Clinical studies have highlighted its effectiveness in improving patient safety and outcomes while reducing opioid usage. Founded in 2008, Medasense is headquartered in Ramat Gan, Tel Aviv, Israel.

Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.

TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.

AesRx is a biopharmaceutical company focused on developing innovative drugs for orphan diseases, particularly sickle cell disease and inflammatory disorders of the lower intestine. Its lead drug candidate, Aes-103, aims to address the complications associated with sickle cell disease, a genetic condition that results in the deformation of red blood cells into rigid shapes, obstructing blood flow and leading to severe health issues such as chronic hemolytic anemia, pain crises, stroke, and acute chest syndrome. By targeting these critical health challenges, AesRx seeks to provide effective therapeutic options for patients suffering from these debilitating conditions.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Chatham Therapeutics LLC operates in the biotechnology sector. The company was formerly known as VECTORRX INC. The company was incorporated in 2010 and is based in Chapel Hill, North Carolina.

Xenetic Biosciences, Inc. is a biopharmaceutical company headquartered in Framingham, Massachusetts, specializing in the development of innovative cancer therapies and drug delivery solutions. The company focuses on advancing its XCART platform, a personalized chimeric antigen receptor T cell technology designed to target patient-specific tumor neoantigens and treat B-cell lymphomas. Additionally, Xenetic is developing its DNase platform to enhance the efficacy of existing cancer treatments by targeting neutrophil extracellular traps, which are linked to cancer progression and treatment resistance. The company also has an investigational drug candidate, XBIO-101, aimed at treating progestin-resistant endometrial cancer. Through collaborations with major pharmaceutical organizations, Xenetic Biosciences leverages its proprietary PolyXen drug delivery technology to improve the performance of various drugs and vaccines across critical medical areas, including oncology.

Covagen is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases and cancer. The company specializes in creating bispecific FynomAbs by genetically fusing its proprietary Fynomer binding proteins to antibodies. This unique approach allows for the design of therapeutics with novel mechanisms of action and improved efficacy. Covagen's lead product, COVA322, is aimed at treating inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company was founded in 2007 as a spin-off from ETH Zurich and has established partnerships to enhance its drug development efforts, including a strategic collaboration with Mitsubishi Tanabe for the development of bispecific FynomAbs targeting specific disease-related pairs. A diverse group of investors supports Covagen’s initiatives, providing the necessary resources to advance its innovative therapeutic candidates.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

The URINFO 2000 fluid monitoring system is the only feasible solution for the accurate, real-time, and continuous monitoring of urine output. The product is based on FlowSense’s patented optical flow sensing technology. URINFO2000 has been used in the critical care setting to optimize fluid and electrolyte balance, treat acute kidney injury, and prevent renal failure.

Gambro is a global medical technology company specializing in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, as well as other extracorporeal treatments for chronic and acute patients. Founded in 1964, Gambro has been a pioneer in dialysis technology, which is critical for patients suffering from organ failure, particularly since kidney transplantation is often not a viable option due to donor shortages. The company innovates in various areas, including hemodialysis, peritoneal dialysis, renal intensive care, and hepatic care, providing solutions that enhance treatment quality and efficiency in clinics and intensive care units. With around 8,000 employees, Gambro operates 13 production facilities across multiple countries and has a presence in more than 90 countries worldwide, demonstrating its commitment to improving patient care through advanced medical technologies.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Zytoprotec GmbH is a biotechnology company based in Vienna, Austria, founded in 2007. It focuses on developing innovative treatment options for kidney failure through its proprietary cytoprotective compounds. The company's primary products include PD-protec, a cytoprotective peritoneal dialysis fluid aimed at enhancing kidney treatment, and ICO-protec, a non-glucose based peritoneal dialysis solution. By restoring the protective mechanisms of cells, Zytoprotec's solutions aim to improve patient outcomes, including survival rates and overall quality of life for individuals undergoing dialysis. The founding team brings extensive experience in business, clinical research, pharmaceutical development, and legal matters, positioning Zytoprotec to make significant advancements in the life sciences sector.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Gliknik Inc. is a biopharmaceutical company based in Baltimore, Maryland, focused on developing therapies for cancer and immune disorders. Founded in 2007, the company offers several innovative treatments, including GL-0817, aimed at preventing the recurrence of squamous cell cancer of the oral cavity, and GL-2045, which targets a range of autoimmune diseases such as immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and Myasthenia gravis. Additionally, Gliknik is advancing GB-4542, an anti-CD20 monoclonal antibody therapy. The company's Immunomodulator Platform includes off-the-shelf peptide drugs to enhance immune responses, while the Stradomer Platform mimics the efficacy of human intravenous immunoglobulin, and the Stradobody Platform produces compounds akin to monoclonal antibodies for tumor cell destruction. Through these efforts, Gliknik aims to provide impactful therapies that alleviate suffering for patients with serious health conditions.

Synovis Life Technologies is a medical device company focused on developing innovative solutions for the surgical and interventional treatment of various diseases. The company specializes in implantable biomaterial devices and offers a range of products designed for microsurgery. Its surgical tools aim to reduce risks and facilitate critical procedures, enhancing the safety and effectiveness of surgical interventions. Through its dedication to advancing medical technology, Synovis Life Technologies contributes to improved patient outcomes in the healthcare sector.

Baxa Corporation is a privately held global company located in Englewood, Colorado. It specializes in the development and distribution of pharmaceutical delivery equipment designed for the preparation, handling, packaging, and administration of liquid medications. The company's medical device platform is utilized in hospitals, critical care units, and alternate-site pharmacies, enabling healthcare providers to administer medications safely and effectively. Baxa's focus is on enhancing the delivery of pharmaceuticals to improve patient care outcomes.

Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company based in King of Prussia, Pennsylvania, founded in 2004. The company specializes in the development and commercialization of cardiovascular injectable products specifically for the United States market. Its notable offerings include NEXTERONE, an injectable antiarrhythmic agent, and PM103, an intravenous formulation of clopidogrel bisulfate.

ApaTech Ltd. is an ortho-biologics company based in Elstree, United Kingdom, specializing in synthetic bone repair materials for surgical applications. Founded in 2001, the company develops innovative products such as Actifuse, a synthetic bone graft that enhances bone formation and is particularly effective for small void filling and spinal fusion. Additionally, ApaTech offers ApaPore, a porous hydroxyapatite grafting solution designed for the revision of failed total joint arthroplasties and the treatment of bone defects. The Actifuse MIS Bone Graft Delivery System provides precise delivery and placement for a range of surgical procedures, including open and minimally invasive operations. ApaTech distributes its products through a network of partners across multiple countries, including those in Europe and Australia. The company also maintains operations in London, Foxborough, Massachusetts, and Berlin, Germany.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

Fusion Medical Technologies manufactures proprietary surgical hemostatic sealant products. It develops collagen gel-based products for use in controlling bleeding in a variety of surgeries.

Somatogen is a biotech company developing a genetically engineered blood substitute.

Caremark provides integrated pharmacy health care services in the United States. It operates through pharmacy services and pharmacy retail. Its pharmacy services include pharmacy benefit management services, such as plan design and administration, formulary management, Medicare part D services, mail order and specialty pharmacy services, prescription management systems, clinical services, disease management, retail pharmacy network management services, discounted drug purchase arrangements, and medical spend management services. Its retail segment provides prescription drugs, over-the-counter drugs, beauty products and cosmetics, seasonal merchandise, greeting cards, and convenience foods, and other related services. It currently operates 7,705 retail drugstores, 860 health care clinics, 17 onsite pharmacies, 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies, 4 mail service dispensing pharmacies, and 84 branches, as well as 6 centers of excellence for infusion and antral services. Caremark provides its services to employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. It was established in 1892 and is headquartered in Woonsocket, Rhode Island. Caremark carries out its operations through its subsidaries.